17 results on '"Shih Te Tu"'
Search Results
2. 2019 Diabetes Atlas: Achievements and challenges in diabetes care in Taiwan
- Author
-
Chih-Cheng Hsu, Shih-Te Tu, and Wayne Huey-Herng Sheu
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Population ,Taiwan ,Type 2 diabetes ,Diabetes Complications ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Epidemiology ,Health care ,Diabetes Mellitus ,Prevalence ,medicine ,Humans ,Child ,education ,Reimbursement, Incentive ,Aged ,Aged, 80 and over ,lcsh:R5-920 ,Type 1 diabetes ,education.field_of_study ,business.industry ,Incidence ,Incidence (epidemiology) ,Mortality rate ,Infant, Newborn ,Infant ,General Medicine ,Middle Aged ,medicine.disease ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,lcsh:Medicine (General) ,business - Abstract
The 2019 Diabetes Atlas delineated both accomplishments and challenges in diabetes care in Taiwan between 2005 and 2014. The series reported that Taiwan had significantly improved aspects of care quality for patients with diabetes. For example, the mortality rate decreased, the difference between the life expectancies of patients with diabetes and those of the general population decreased, and the rates of hospitalization because of heart diseases, cerebrovascular diseases, chronic kidney diseases, and unsatisfactory glycemic control decreased. However, despite these achievements, the 2019 Diabetes Atlas also reported some substantial challenges that have not been overcome. For example, the incidence of diabetes among women aged
- Published
- 2019
3. National survey of ABC (A1C, blood pressure, cholesterol) of Diabetes Health Promotion Institutes in Taiwan: 2002–2018
- Author
-
Chih-Yuan Wang, Wayne Huey-Herng Sheu, Shih-Te Tu, Ming-Shiang Wu, Chong-Jen Yu, I-Chun Chen, and Lee-Ming Chuang
- Subjects
medicine.medical_specialty ,Taiwan ,MEDLINE ,Blood Pressure ,030209 endocrinology & metabolism ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,030212 general & internal medicine ,Glycated Hemoglobin ,business.industry ,Cholesterol ,Cholesterol, LDL ,General Medicine ,medicine.disease ,Health Surveys ,Cholesterol blood ,Health promotion ,Blood pressure ,Diabetes Mellitus, Type 2 ,chemistry ,business - Published
- 2018
4. High diabetes mellitus prevalence with increasing trend among newly-diagnosed tuberculosis patients in an Asian population: A nationwide population-based study
- Author
-
Yu-Cheng Chen, Shi-Dou Lin, Shang-Ren Hsu, Po-Yen Ko, Shih-Te Tu, Ming-Chia Hsieh, and Shih-Li Su
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Tuberculosis ,Databases, Factual ,Endocrinology, Diabetes and Metabolism ,030231 tropical medicine ,Taiwan ,Prevalence ,Comorbidity ,Disease ,03 medical and health sciences ,Liver disease ,Age Distribution ,0302 clinical medicine ,Risk Factors ,Diabetes mellitus ,Diabetes Mellitus ,Odds Ratio ,Internal Medicine ,medicine ,Humans ,030212 general & internal medicine ,Aged ,Chi-Square Distribution ,Nutrition and Dietetics ,Vascular disease ,business.industry ,Middle Aged ,medicine.disease ,Health Surveys ,Cross-Sectional Studies ,Logistic Models ,Multivariate Analysis ,Female ,Family Practice ,business ,Dyslipidemia ,Kidney disease - Abstract
Aims Our aims were to investigate the prevalence of diabetes mellitus (DM) among patients with newly-diagnosed tuberculosis (TB) and to determine its associated factors in an Asian population. Methods The data were obtained from the National Health Insurance Research Database and included 9831 newly-diagnosed TB individuals in the period of 2000–2010. The data were divided into a DM group and a non-DM group. We measured the prevalence and the associated comorbidities of DM. Results During 2000–2010, the prevalence of DM progressively increased, with an average prevalence rate of 27.9%. The patients with ages of 55–64 years had the highest association of DM (OR = 3.53) compared with those under 45 years. TB patients with heart failure, ischemic heart disease, cerebral vascular disease, hypertension, dyslipidemia, chronic kidney disease, and liver disease were more likely to associate with DM (ORs = 1.27, 1.23, 1.30, 2.32, 3.26, 1.6, and 1.68, respectively) compared to those without the variables. Conclusions The prevalence of DM among TB patients in Taiwan was high and tended to increase in the past decade. Clinically, inquiring about DM history and screening routinely for those without DM history among TB patients should be carried out in Taiwan.
- Published
- 2016
5. Glycemic excursions are positively associated with changes in duration of asymptomatic hypoglycemia after treatment intensification in patients with type 2 diabetes
- Author
-
Jun-Sing Wang, Shih-Li Su, Shih-Yi Lin, Yao-Hsien Tseng, Wayne Huey-Herng Sheu, Shih-Te Tu, I.-Te Lee, Wen-Jane Lee, and Shi-Dou Lin
- Subjects
Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Monitoring, Ambulatory ,030209 endocrinology & metabolism ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Hypoglycemia ,Gastroenterology ,Glibenclamide ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Endocrinology ,Internal medicine ,Diabetes mellitus ,Glyburide ,Internal Medicine ,medicine ,Humans ,Hypoglycemic Agents ,Aged ,Acarbose ,Glycemic ,Glycated Hemoglobin ,business.industry ,nutritional and metabolic diseases ,General Medicine ,Middle Aged ,medicine.disease ,Metformin ,Diabetes Mellitus, Type 2 ,chemistry ,Drug Therapy, Combination ,Female ,Glycated hemoglobin ,business ,medicine.drug - Abstract
Aim The aim of this study was to examine the association between glycemic excursions and duration of hypoglycemia after treatment intensification in patients with type 2 diabetes (T2D). Methods Patients with T2D on oral anti-diabetes drug (OAD) with glycated hemoglobin (HbA1c) of 7.0–11.0% were switched to metformin monotherapy (500mg thrice daily) for 8 weeks, followed by randomization to either glibenclamide or acarbose as add-on treatment for 16 weeks. Glycemic excursions were assessed as mean amplitude of glycemic excursions (MAGE) with 72-h ambulatory continuous glucose monitoring (CGM) before randomization and at the end of study. Hypoglycemia was defined as sensor glucose level of less than 60mg/dl in two or more consecutive readings from CGM. Results A total of 50 patients (mean age 53.5±8.2 years, male 48%, mean baseline HbA1c 8.4±1.2%) were analyzed. Duration of hypoglycemia significantly increased after treatment with glibenclamide (from 5.5±13.8 to 18.8±35.8min/day, p =0.041), but not with acarbose (from 2.9±10.9 to 14.7±41.9min/day, p =0.114). Post treatment MAGE was positively associated with change from baseline in duration of hypoglycemia after treatment with either glibenclamide ( β coefficient 0.345, p =0.036) or acarbose ( β coefficient 0.674, p =0.046). The association remained significant after multivariate adjustment ( p Conclusions Post treatment glycemic excursions are associated with changes in duration of hypoglycemia after treatment intensification with OAD in patients with T2D. Glycemic excursions should be an important treatment target for T2D to reduce the risk of hypoglycemia.
- Published
- 2016
6. Effects of high-dose phytoestrogens on circulating cellular microparticles and coagulation function in postmenopausal women
- Author
-
Hui-Yu Peng, I-Shaw Jan, Ssu-Chun Hsu, Chih Hsing Wu, Shu-Yi Wang, Chao-Wei Liu, Ning-Sing Shaw, Ching-I Chang, Wern-Cherng Cheng, Keh-Sung Tsai, Chi-Ling Chen, Tong-Yuan Tai, Li-Na Lee, Jin-Shan Wu, Shih-Te Tu, and Shyi-Chyi Lo
- Subjects
medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Taiwan ,Physiology ,postmenopausal women ,coagulation factors ,Placebo ,Double-Blind Method ,Cell-Derived Microparticles ,Internal medicine ,Coagulation testing ,Medicine ,Humans ,Prospective Studies ,isoflavones ,Blood Coagulation ,microparticles ,phytoestrogens ,Medicine(all) ,lcsh:R5-920 ,Hematology ,medicine.diagnostic_test ,business.industry ,Hormone replacement therapy (menopause) ,General Medicine ,Middle Aged ,medicine.disease ,Blood Coagulation Factors ,Healthy Volunteers ,Menopause ,Postmenopause ,Endocrinology ,Blood pressure ,Estrogen ,Female ,lcsh:Medicine (General) ,business ,Liver function tests ,Biomarkers - Abstract
Background/Purpose Estrogen in hormone replacement therapy causes homeostatic changes. However, little is known regarding the safety of high-dose phytoestrogen on coagulation and hematological parameters in healthy postmenopausal women. This study evaluated the effects of high-dose soy isoflavone (300 mg/day) on blood pressure, hematological parameters, and coagulation functions including circulating microparticles in healthy postmenopausal women. Methods The original study is a 2-year prospective, double-blind, placebo-controlled study. In total, 431 postmenopausal women (from 3 medical centers) were randomly assigned to receive either high-dose isoflavone or placebo for 2 years. At baseline, 6 months, 1 year, and 2 years after treatment, blood pressure, body weight, liver function tests, hematological parameters, and lipid profiles were measured. The 1 st year blood specimens of 85 cases of 144 eligible participants (from one of the three centers) were analyzed as D-dimer, von Willebrand factor antigen, factor VII, plasminogen activator inhibitor type 1, and circulating cellular microparticles, including the measurement of monocyte, platelet, and endothelial microparticles. Results In the isoflavone group, after 1 year, the changes in liver function tests, hematological parameters, and coagulation tests were not different from those of the control. Triglyceride levels were significantly lower after 6 months of isoflavone treatment than the placebo group, but the difference did not persist after 1 year. Endothelial microparticles increased steadily in both groups during the 1-year period but the trend was not affected by treatment. Conclusion The results of the present study indicate that high-dose isoflavone treatment (300 mg/day) does not cause hematological abnormalities or activate coagulation factors.
- Published
- 2015
- Full Text
- View/download PDF
7. Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes
- Author
-
Chieh-Hsiang Lu, Jung-Fu Chen, Neng-Chun Yu, Ching-Chieh Su, Chao-Hung Wang, Shih-Tzer Tsai, Shi-Dou Lin, Shih-Te Tu, Ming-Chia Hsieh, and Shang-Ren Hsu
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Time Factors ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Taiwan ,Administration, Oral ,Type 2 diabetes ,Demographic data ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,Humans ,Hypoglycemic Agents ,Insulin ,Medicine ,Aged ,Retrospective Studies ,Glycemic ,Glycated Hemoglobin ,Nutrition and Dietetics ,business.industry ,Basal insulin ,Middle Aged ,medicine.disease ,Surgery ,Treatment Outcome ,Diabetes Mellitus, Type 2 ,Drug Therapy, Combination ,Female ,Observational study ,Hemoglobin ,Family Practice ,business ,Biomarkers - Abstract
Factors predicting success (glycosylated hemoglobin (A1C)7%) with insulin therapy in patients with insulin-requiring type 2 diabetes need to be identified.A retrospective, multi-center, observational study was conducted for outpatients with oral antidiabetic drug (OAD)-treated type 2 diabetes whose A1C levels remained above 7%. Patients were begun on basal insulin between January 2005 and December 2006. Biochemical variables and demographic data were collected before and after 52 weeks of insulin therapy.A total of 565 patients (age, 60.4±11.9 years; A1C levels, 10.11 ±1.81%; duration of diabetes, 11.5±6.8 years) were studied. By study end, 63 patients (11.2%) had achieved the glycemic goal (A1C7%). The glycemic goal attainment rate was only 9.1% in patients with A1C8.8% and who were taking2 OADs at baseline. The highest rate (32.7%) of successful glycemic control was observed in the group of patients with A1C ≤ 8.8% and who used ≤ 2 OADs at baseline.Insulin-naïve diabetic patients with A1C8.8%, especially those who are taking2 OADs, have small chance to achieve good glycemic control with adding only basal insulin therapy.
- Published
- 2015
8. Hospital-based integrated diabetes care management: An overview
- Author
-
Bai-Ling Syu, Jia-Yu Tian, I-Chieh Mao, Guan-Yi Lin, Ya-You Syu, Wen-Hui Chen, Yi-Wen Cho, Jeng-Fu Kuo, Tzu-Ying Wu, Yan-Chi Li, Shang-Ren Hsu, Chia-Ching Hsu, and Shih-Te Tu
- Subjects
Male ,Delivery of Health Care, Integrated ,business.industry ,Endocrinology, Diabetes and Metabolism ,Disease Management ,Information technology ,Quality care ,General Medicine ,Hospital based ,Middle Aged ,medicine.disease ,Hospitals ,Endocrinology ,Nursing ,Ambulatory care ,Diabetes mellitus ,Diabetes Mellitus ,Internal Medicine ,Humans ,Medicine ,Female ,business ,Aged ,Quality of Health Care ,Retrospective Studies - Abstract
To provide continuous, accessible, and quality care, a diabetes share-care program has been in place in Taiwan for several years. Lukang Christian Hospital, a member of the diabetes share-care network, endeavors to provide "patient-centered" care aimed at increasing care quality and reducing diabetic complications. Information technology has been employed by the hospital for monitoring care quality and analyzing cost-effectiveness. Structured health-care programs have also been developed to ensure the completeness of diabetes care and to encourage self-management of individuals at high risk for diabetes. The implementation of these strategies has led to progressive improvement in quality measures and spawned novel and creative ways to deliver care services.
- Published
- 2014
9. Obesity and low target attainment rates in Chinese with type 2 diabetes
- Author
-
Yi-Ting Hsieh, Xing-Bo Cheng, Ming-Chia Hsieh, and Shih-Te Tu
- Subjects
Male ,China ,medicine.medical_specialty ,Statin ,medicine.drug_class ,Cross-sectional study ,Blood Pressure ,Type 2 diabetes ,Body Mass Index ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,Humans ,Obesity ,Triglycerides ,Aged ,business.industry ,Cholesterol, HDL ,Cholesterol, LDL ,Middle Aged ,medicine.disease ,Metformin ,Cross-Sectional Studies ,Blood pressure ,Diabetes Mellitus, Type 2 ,Physical therapy ,Female ,business ,Body mass index ,medicine.drug - Abstract
Background Although it is known that the prevalence of type 2 diabetes and obesity is increasing in China, there is little research into how obese or non-obese patients may differ in their attainment of treatment goals for type 2 diabetes. To do this, we assessed the attainment of American Diabetes Association (ADA)-recommended goals in Chinese with type 2 diabetes stratified by body mass index (BMI). Methods This cross-sectional study enrolled 520 Chinese with type 2 diabetes to find out if they had attained the following ADA-recommended goals: HbA1c 40 mg/dl for men and > 50 mg/dl for women. Results Only 44.4% of all participants achieved the blood pressure goal, 20.8% the HbA1c goal, 44.8% the LDL-C goal, 43.3% the HDL-C goal, and 66.8% the triglyceride goal. Obese patients were less likely than normal weight patients to achieve the blood pressure goal (OR, 0.474; 95% CI, 0.231–0.973; p = 0.01), the HDL goal (OR, 0.365; 95% CI, 0.163–0.817; p = 0.01), or the triglyceride goal (OR, 0.416; 95% CI, 0.212–0.817; p = 0.01), after adjusting for confounders. Compared to normal weight participants, the obese patients had a significantly higher prescription rates for statin, metformin and anti-hypertensive drugs. Conclusion Obese diabetic patients were less likely to achieve the blood pressure, LDL-C, HDL-C and triglyceride targets even when they were receiving several drugs to help them meet their target treatment goals. More strategies are needed to improve the treatment of Chinese with type 2 diabetes, particularly those who are obese.
- Published
- 2012
10. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data
- Author
-
Jun-Sing Wang, Ming-Chia Hsieh, Shih-Yi Lin, Shang-Ren Hsu, I-Te Lee, Shu-Yi Wang, Shih-Te Tu, Wayne H-H Sheu, Shi-Dou Lin, and Shih-Li Su
- Subjects
Adult ,Blood Glucose ,Male ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Drug Resistance ,Taiwan ,Monitoring, Ambulatory ,Type 2 diabetes ,Pharmacology ,Glibenclamide ,Endocrinology ,Diabetes mellitus ,Weight Loss ,Internal Medicine ,medicine ,Humans ,Hypoglycemic Agents ,Glycoside Hydrolase Inhibitors ,Enzyme Inhibitors ,Aged ,Glycemic ,Acarbose ,Glycated Hemoglobin ,business.industry ,Middle Aged ,medicine.disease ,Sulfonylurea ,Hypoglycemia ,Metformin ,Postprandial ,Diabetes Mellitus, Type 2 ,Hyperglycemia ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Although sulfonylurea added to metformin is the first oral drug combination regimen for patients with type 2 diabetes recommended by the American Diabetes Association/European Association for the Study of Diabetes consensus statement, it does not allow for individualizing and optimizing therapy with respect to sustaining glycemic control and the reduction of glucose variability. We therefore sought to investigate acarbose as an alternative to glibenclamide in combination with metformin and compare the effects on metabolic control and glucose variability.Type 2 diabetic patients 30-70 years of age with glycosylated hemoglobin 7.0%-11.0% while treated with one or two oral antidiabetic drugs were successively enrolled. After 8 weeks of run-in with metformin 500 mg thrice daily, either acarbose 50 mg or glibenclamide 2.5 mg three times daily was randomly added on and force titrated to acarbose 100 mg or glibenclamide 5.0 mg three times daily for the subsequent 16 weeks. Demographic data, biochemical data and continuous glucose monitoring system data were recorded upon randomization and at the end of the study. Various parameters that measure glucose variability were derived from the continuous glucose monitoring system data.Of the 51 type 2 diabetes patients enrolled, data from 40 subjects, 20 in each group, were analyzed after excluding those unqualified information. Both drug combinations improved glycemic control. Glucose variability, expressed as mean amplitude of glycemic excursion or continuous overall net glycemic action and mean of daily differences, decreased significantly (all P.05) after the addition of acarbose but not glibenclamide. The acarbose-metformin combination has the additional benefits of weight reduction and shorter durations of hyperglycemia compared with metformin monotherapy.This study suggests that both intraday and interday glucose variability are more effectively reduced by the acarbose-metformin combination than by the glibenclamide-metformin combination, while both combinations reduce the overall glucose level equally.
- Published
- 2011
11. Common polymorphisms of the peroxisome proliferator-activated receptor–γ (Pro12Ala) and peroxisome proliferator-activated receptor–γ coactivator–1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus
- Author
-
Shun-Jen Chang, Shiu-Ru Lin, Hung-Chun Chen, Kun-Der Lin, Kai-Jen Tien, Shih-Te Tu, Jeng-Yueh Hsiao, Ming-Chia Hsieh, and Shih-Jang Shing
- Subjects
Adult ,Male ,Agonist ,medicine.medical_specialty ,Genotype ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Peroxisome proliferator-activated receptor ,Type 2 diabetes ,Endocrinology ,Asian People ,Polymorphism (computer science) ,Internal medicine ,medicine ,Humans ,Hypoglycemic Agents ,Allele ,Receptor ,Heat-Shock Proteins ,Aged ,Glycated Hemoglobin ,chemistry.chemical_classification ,Polymorphism, Genetic ,Pioglitazone ,business.industry ,Type 2 Diabetes Mellitus ,Middle Aged ,medicine.disease ,Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha ,PPAR gamma ,Diabetes Mellitus, Type 2 ,chemistry ,Female ,Thiazolidinediones ,business ,Transcription Factors ,medicine.drug - Abstract
We investigated the effects of the common polymorphisms in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma; Pro12Ala) and in PPAR-gamma coactivator-1(PGC-1; Gly482Ser) genes on the response to pioglitazone in Chinese with type 2 diabetes mellitus. A total of 250 patients with type 2 diabetes mellitus were treated with pioglitazone (30 mg/d) for 24 weeks without a change in previous medications. All patients were genotyped for the PPAR-gamma Pro12Ala and PGC-1 Gly482Ser polymorphisms. The Ala12Ala and Pro12Ala genotypes (26.0% vs 13.5%, P = .025) and Ala allele (15.6% vs 7.3%, P = .008) were significantly more frequent in pioglitazone responders than in nonresponders. The distribution of PGC-1 genotypes and alleles was not significantly different between responders and nonresponders. The decrease in fasting glucose (50.4 +/- 52.2 vs 43.3 +/- 51.7 mg/dL, P.001) and hemoglobin A(1c) (0.57% +/- 1.44% vs 0.35% +/- 1.10%, P = .004) levels was significantly greater in subjects with the Ala12 carriers (Pro12Ala and Ala12Ala) than in those without the allele (Pro12Pro). Baseline fasting glucose and triglyceride levels were related to the response of pioglitazone. Only the PPAR-gamma Pro12Ala polymorphism was found to be associated with the response of pioglitazone by multiple logistic regression analysis. The PPAR-gamma Pro12Ala gene polymorphism is associated with the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. These findings may be helpful for targeted treatment of diabetes by identifying patients who are likely to respond to pioglitazone.
- Published
- 2010
12. Diabetic nephropathy and risk factors for peripheral artery disease in Chinese with type 2 diabetes mellitus
- Author
-
Jeng-Yueh Hsiao, Shih-Te Tu, Shun-Jen Chang, Hung-Chun Chen, Daw-Shyong Perng, Ming-Chia Hsieh, Kai-Jen Tien, and Hui-Ting Liang
- Subjects
Male ,China ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Renal function ,Type 2 diabetes ,Diabetic nephropathy ,chemistry.chemical_compound ,Endocrinology ,Risk Factors ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Diabetic Nephropathies ,Risk factor ,Aged ,Peripheral Vascular Diseases ,Creatinine ,business.industry ,Type 2 Diabetes Mellitus ,Middle Aged ,medicine.disease ,Diabetes Mellitus, Type 2 ,chemistry ,Female ,business ,Diabetic Angiopathies ,Kidney disease - Abstract
The risk for peripheral arterial disease (PAD) is increased in patients with chronic kidney disease. We investigated the effects of renal function on PAD in Chinese with type 2 diabetes mellitus. This study enrolled a total of 2983 (1342 men and 1641 women) Chinese adults with diabetes. The mean age was 63.2 +/- 11.9 years. Peripheral arterial disease was diagnosed by an ankle-brachial index less than 0.9. Renal function was evaluated by serum creatinine (SCr), estimated glomerular filtration rate, and urinary albumin-creatinine ratio (ACR). Risk factors for PAD were evaluated using multiple logistic regression analysis. Age, cholesterol, and high-density lipoprotein cholesterol (HDL-C) (inverse association) were significant risk factors in men, whereas age, body mass index (inverse association), low-density lipoprotein cholesterol, and HDL-C (inverse association) were significant risk factors for diabetic women. After adjustment for age, body mass index, blood pressure, glycosylated hemoglobin, cholesterol, HDL-C, low-density lipoprotein cholesterol, and triglyceride levels, we found that SCr levels greater than 1.5 mg/dL, estimated glomerular filtration rate less than 60 mL/min, and urinary ACR greater than 30 mg/g were independent risk factors for PAD in diabetic men and that SCr levels greater than 1.4 mg/dL and urinary ACR greater than 30 mg/g were independently associated with PAD in diabetic women. The risk factors for PAD are somewhat different between men and women with diabetes in Chinese population in Taiwan. Diabetic nephropathy is significantly associated with PAD in this patient population.
- Published
- 2009
13. The anti-hyperglycemic activity of the fruiting body of Cordyceps in diabetic rats induced by nicotinamide and streptozotocin
- Author
-
Su-Chen Lin, Hui-Chen Lo, Shih-Te Tu, and Kwo-Chuan Lin
- Subjects
Blood Glucose ,Male ,Niacinamide ,medicine.medical_specialty ,Administration, Oral ,Weight Gain ,Streptozocin ,General Biochemistry, Genetics and Molecular Biology ,Diabetes Mellitus, Experimental ,chemistry.chemical_compound ,Weight loss ,Diabetes mellitus ,Internal medicine ,medicine ,Animals ,Hypoglycemic Agents ,Insulin ,Rats, Wistar ,General Pharmacology, Toxicology and Pharmaceutics ,Pancreas ,Cordyceps ,Glucose tolerance test ,biology ,medicine.diagnostic_test ,Nicotinamide ,business.industry ,food and beverages ,Organ Size ,General Medicine ,Glucose Tolerance Test ,biology.organism_classification ,medicine.disease ,Streptozotocin ,Diet ,Rats ,Disease Models, Animal ,Endocrinology ,Fructosamine ,chemistry ,Fruit ,medicine.symptom ,business ,Weight gain ,Drugs, Chinese Herbal ,medicine.drug - Abstract
Little scientific evidence exists to support the numerous herbs used to improve diabetes-related metabolic disorders. Cordyceps, a Chinese herbal medicine with fruiting body and carcass, has been proposed to have multiple medicinal activities. The objective of this study was to investigate the effects of fruiting body and carcass of Cordyceps on hyperglycemia. Male Wistar rats administered with placebo (STZ group), 1 g of fruiting body (FB group), 1 g of carcass (CC group), or 1g of fruiting body plus carcass (CF group) of Cordyceps for four weeks (d1 to d28) were injected with nicotinamide (200 mg/kg) and streptozotocin (65 mg/kg) on d15. Animals fed with placebo and injected with saline acted as the controls (CON group). The results showed that water intake (d15 to d29), changes in fasting blood glucose concentration (d15 to d26), and serum concentrations of fructosamine (d29) were significantly greater in the STZ, CC and CF groups than in the CON and FB groups (one-way ANOVA, P < 0.05). The diabetic rats had significantly lower weight gain and higher blood glucose response in oral glucose tolerance test than the control rats; and these changes were significantly reduced by administrating the fruiting body of Cordyceps. Our results revealed that fruiting body, not carcass, of Cordyceps attenuated the diabetes-induced weight loss, polydipsia and hyperglycemia, and these improvements suggest that fruiting body of Cordyceps has a potential to be the functional food for diabetes.
- Published
- 2004
14. The evaluation of patients’ use of tele-health program
- Author
-
Shih-Te Tu
- Subjects
Endocrinology ,business.industry ,Endocrinology, Diabetes and Metabolism ,Diabetes mellitus ,Internal Medicine ,medicine ,General Medicine ,Tele health ,Medical emergency ,medicine.disease ,business - Published
- 2016
15. A study of increasing access to diabetic retinopathy screening and referral if indicated
- Author
-
Shih-Te Tu, Yen-Tzu Lee, Yu-Ying Chang, and I-chieh Mao
- Subjects
medicine.medical_specialty ,Referral ,business.industry ,Endocrinology, Diabetes and Metabolism ,Diabetic retinopathy screening ,General Medicine ,medicine.disease ,Endocrinology ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,Medicine ,Optometry ,business - Published
- 2016
16. Periodontitis prevention program effectively reduced the incidence of periodontitis in diabetic patients
- Author
-
Yen-Tzu Lee, I-chieh Mao, and Shih-Te Tu
- Subjects
Periodontitis ,medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,Incidence (epidemiology) ,Dentistry ,General Medicine ,medicine.disease ,Endocrinology ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,business - Published
- 2016
17. Surgical site infections after orthopedics operation: Outbreak investigation and surveillance
- Author
-
Chun-Eng Liu, Chao-jen Lin, Shih-Te Tu, Hui-chu Lin, and Ming-Tang Song
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,General Immunology and Microbiology ,business.industry ,General surgery ,Outbreak ,General Medicine ,Surgery ,Infectious Diseases ,Immunology and Microbiology(all) ,Surgical site ,Orthopedic surgery ,Immunology and Allergy ,Medicine ,business - Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.